Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women who have been diagnosed with high grade serous ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy (meaning the cancer got worse within 6 months of the last platinum chemotherapy).
• People whose cancer can be measured on scans or physical examination, meeting specific size thresholds set out in the trial.
• People who have at least one tumour site that can be safely biopsied before and during treatment, and who agree to those biopsies.
• People who have had surgery, provided at least 28 days have passed since the procedure and the wound has healed.
• People who have received any number of prior chemotherapy regimens for platinum-sensitive disease, but no more than one chemotherapy regimen for platinum-resistant disease.
• People who have previously received a type of cancer treatment called an immune checkpoint inhibitor, as long as it was not stopped due to serious or recurring severe side effects (such as heart inflammation, brain inflammation, severe bowel problems, or other listed serious reactions).
• People whose last cancer treatment was at least 4 weeks before enrolling, and whose side effects from prior treatment have mostly resolved.
• People who have had radiation, hormone therapy, or certain other non-cancer investigational treatments, provided at least 28 days have passed since the last dose.
• People who are reasonably physically well and active, with an ECOG performance status of 0 or 1 (confirm with trial site), and who are expected to live at least 3 months or more.
• People aged 18 years or older.
• People who agree to provide a stored tumour tissue sample (or undergo a biopsy if no stored sample is available), and to have biopsies taken before and during treatment.
• People who are willing and able to attend scheduled visits, follow testing requirements, and complete the trial as planned.
• People whose blood test results, taken within 7 days before enrolling, show that the bone marrow, liver, and kidneys are functioning within the levels required by the trial.
• People who live within a reasonable travelling distance of a participating trial centre (for example, approximately 1.5 hours' driving distance).
• People who agree to return to their treating centre for side effect monitoring, response assessments, and follow-up throughout the trial.
• Women of childbearing potential who undergo a pregnancy test as part of the pre-study evaluation.

Who may not be able to join:

• People with a history of another cancer, unless it was treated with curative intent and does not interfere with assessing the safety or effectiveness of the trial treatment (this must be confirmed with the trial team).
• People with serious or uncontrolled medical conditions, including: a history of an abdominal abscess within the past 3 months; active serious infection or chronic liver disease needing ongoing treatment; active or known HIV, hepatitis B, or hepatitis C infection with detectable virus or requiring antiviral treatment; a history of lung scarring conditions or severe lung disease; significant fluid build-up around the lungs, heart, or abdomen that affects organ function or requires draining; autoimmune disease requiring long-term steroid use; a stroke or mini-stroke (TIA) within the past 6 months; or a significant heart problem such as a heart attack, unstable chest pain, or heart failure within the past 6 months; or a history of stem cell or organ transplantation.
• People who have cancer that has spread to the brain and is causing symptoms requiring steroid treatment.
• People who have had spinal cord compression, unless they have been definitively treated and their condition has been stable for at least 28 days before starting the trial.
• Women who are pregnant or breastfeeding.
• People who are currently receiving other cancer treatments or other investigational anti-cancer treatments at the same time.
• People who have had certain active or documented autoimmune or inflammatory conditions within the past 3 years, such as inflammatory bowel disease, lupus, rheumatoid arthritis, sarcoidosis, or similar conditions. (Note: some lower-risk conditions such as vitiligo, well-controlled type 1 diabetes, thyroid conditions only needing hormone replacement, or mild psoriasis not requiring systemic treatment may still be eligible.)
• People who have received a live vaccine within 4 weeks before enrolling. (Note: standard inactivated flu vaccines are permitted, but nasal spray flu vaccines, which are live, are not.)
• People whose heart's electrical activity (measured on an ECG) shows a prolonged interval called the QTc, above the thresholds set by the trial, or who take medications known to affect this measurement.

Important: Always verify eligibility with the trial site directly before applying.